Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A
lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Your browser is not supported
Switch to Chrome, Edge, Firefox or Safari
This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.
This Clinical Guide provides comprehensive, national guidance for optimal management of pregnant and parenting women with opioid use disorder and their infants. The Clinical Guide helps healthcare professionals and patients determine the most clinically appropriate action for a particular situation and informs individualized treatment decisions.
This information sheet, for practitioners, explains the importance of concurrent treatment of OUD with prenatal/postpartum care and the importance of providing the materials to clients.
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
This fact sheet is for women who are pregnant or of childbearing age with an opioid use disorder
This updated (March 2020) TIP is intended to provide addiction counselors and other providers, supervisors, and administrators with the latest science in the screening, assessment, diagnosis, and management of co-occurring disorders (CODs).
